Cited by 1,268Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline

Näslund, Jan·2000·JAMA

DOI 10.1001/jama.283.12.1571

Open this paper in CoChat — free account

Abstract

CONTEXT: Alzheimer disease (AD) is characterized neuropathologically by the presence of amyloid beta-peptide (Abeta)-containing plaques and neurofibrillary tangles composed of abnormal tau protein. Considerable controversy exists as to whether the extent of accumulation of Abeta correlates with dementia and whether Abeta alterations precede or follow changes in tau. OBJECTIVES: To determine whether accumulation of Abeta correlates with the earliest signs of cognitive deterioration and to define the relationship between Abeta accumulation and early tau changes. DESIGN, SETTING, AND PATIENTS: Postmortem cross-sectional study of 79 nursing home residents with Clinical Dementia Rating (CDR) scale scores of 0.0 to 5.0 who died between 1986 and 1997, comparing the levels of Abeta variants in the cortices of the subjects with no (CDR score, 0.0 [n = 16]), questionable (CDR score, 0.5 [n = 11]), mild (CDR score, 1.0 [n = 22]), moderate (CDR score, 2.0 [n = 15]), or severe (CDR score, 4.0 or 5.0 [n = 15]) dementia. MAIN OUTCOME MEASURES: Levels of total Abeta peptides with intact or truncated amino termini and ending in either amino acid 40 (A(beta)x-40) or 42 (A(beta)x-42) in 5 neocortical brain regions as well as levels of tau protein undergoing early conformational changes in frontal cortex, as a function of CDR score. RESULTS: The levels of both A(beta)x-40 and A(beta)x-42 were elevated even in cases classified as having questionable dementia (CDR score = 0.5), and increases of both peptides correlated with progression of dementia. Levels of the more fibril-prone A(beta)x-42 peptide were higher than those of A(beta)x-40 in nondemented cases and remained higher throughout progression of disease in all regions examined. Finally, increases in A(beta)x-40 and A(beta)x-42 precede significant tau pathology at least in the frontal cortex, an area chosen for examination because of the absence of neuritic changes in the absence of disease. CONCLUSIONS: In this study, levels of total A(beta)x-40 and A(beta)x-42 were elevated early in dementia and levels of both peptides were strongly correlated with cognitive decline. Of particular interest, in the frontal cortex, Abeta was elevated before the occurrence of significant tau pathology. These results support an important role for Abeta in mediating initial pathogenic events in AD dementia and suggest that treatment strategies targeting the formation, accumulation, or cytotoxic effects of Abeta should be pursued.

Integrity signals

Registry

Crossref · 10.1001/jama.283.12.1571

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
Yankner, B. A. (1996) · Neuron · doi:10.1016/s0896-6273(00)80115-4 · Cited by 953
Alzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 879
Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide
Haass, C., & Selkoe, D. J. (1993) · Cell · doi:10.1016/0092-8674(93)90312-e · Cited by 686
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits
Bierer, L. M., Haroutunian, V. H., Gabriel, S., Knott, P. J., Carlin, L. S., Purohit, D. P., Perl, D. P., Schmeidler, J., Kanof, P. D., & Davis, K. L. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020749.x · Cited by 580

Show all 28 references

Sorted by citations

Items 501–600 of 1,000

Morphometric Changes in the Episodic Memory Network and Tau Pathologic Features Correlate with Memory Performance in Patients with Mild Cognitive Impairment
Fjell, A. M., Walhovd, K. B., Amlien, I. K., Bjørnerud, A., Reinvang, I., Gjerstad, L., Cappelen, T., Willoch, F., Due‐Tønnessen, P., Grambaitė, R., et al. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1059 · Cited by 61
Ventricular and Periventricular Anomalies in the Aging and Cognitively Impaired Brain
Todd, K. L., Brighton, T., Norton, E. S., Schick, S., Elkins, W., Pletniková, O., Fortinsky, R. H., Troncoso, J. C., Molfese, P. J., Resnick, S. M., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00445 · Cited by 62
Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Aβ(1–42) injections in the rat
Richardson, R. L., Kim, E.-M., Shephard, R. A., Gardiner, T. A., Cleary, J. P., & O‘Hare, E. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03006-8 · Cited by 62
Mouse Genetic Models of Human Brain Disorders
Leung, C., & Jia, Z. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00040 · Cited by 63
Drosophila Models of Alzheimer's Amyloidosis: The Challenge of Dissecting the Complex Mechanisms of Toxicity of Amyloid-β 42
Iijima, K., & Iijima‐Ando, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15402 · Cited by 61
The immune system, amyloid‐β peptide, and Alzheimer's disease
Weksler, M. E., Gouras, G. K., Relkin, N. R., & Szabo, P. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00264.x · Cited by 60
β-Amyloid Peptide Activates Non-α7 Nicotinic Acetylcholine Receptors in Rat Basal Forebrain Neurons
Fu, W., & Jhamandas, J. H. (2003) · Journal of Neurophysiology · doi:10.1152/jn.00616.2003 · Cited by 59
Passive Immunization against β-Amyloid Peptide Protects Central Nervous System (CNS) Neurons from Increased Vulnerability Associated with an Alzheimer’s Disease-causing Mutation
Mohajeri, M. H., Saini, K., Schultz, J. G., Wollmer, M. A., Höck, C., & Nitsch, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203193200 · Cited by 62
Retromer Sorting
Small, S. A. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.64 · Cited by 58
The Merits of FDDNP-PET Imaging in Alzheimer's Disease
Shin, J., Kepe, V., Barrio, J. R., & Small, G. W. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0008 · Cited by 62
Neuronal Aβ42 is enriched in small vesicles at the presynaptic side of synapses
Yu, Y., Jans, D. C., Winblad, B. G., Tjernberg, L. O., & Schedin‐Weiss, S. (2018) · Life Science Alliance · doi:10.26508/lsa.201800028 · Cited by 60
A case for a non‐transgenic animal model of Alzheimer's disease
Stéphan, A., & Phillips, A. G. (2005) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2004.00113.x · Cited by 63
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease
Villemagne, V. L., Klunk, W. E., Mathis, C. A., Rowe, C. C., Brooks, D. J., Hyman, B. T., Ikonomović, M. D., Ishii, K., Jack, C. R., Jagust, W. J., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2045-0 · Cited by 58
Role of Ca2+/Calmodulin-Dependent Protein Kinase Type II in Mediating Function and Dysfunction at Glutamatergic Synapses
Mohanan, A. G., Gunasekaran, S., Jacob, R. S., & Omkumar, R. V. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.855752 · Cited by 55
Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer’s disease and apoE TR mouse cortex
Arold, S. P., Sullivan, P. M., Bilousova, T. V., Teng, E., Miller, C. A., Poon, W. W., Vinters, H. V., Cornwell, L. B., Saing, T., Cole, G. M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0892-1 · Cited by 58
Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase study
Saumier, D., Duong, A., Haine, D., Garceau, D., & Sampalis, J. S. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0217-4 · Cited by 57
AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly
Sokolow, S., Henkins, K. M., Bilousova, T. V., Miller, C. A., Vinters, H. V., Poon, W. W., Cole, G. M., & Gylys, K. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.011 · Cited by 61
Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice
Park, M. H., Lee, J. K., Choi, S., Ahn, J., Jin, H. K., Park, J., & Bae, J. (2013) · Brain Research · doi:10.1016/j.brainres.2013.05.045 · Cited by 59
The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer’s disease
Lau, H. H. C., Ingelsson, M., & Watts, J. C. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02201-2 · Cited by 57
Relationship between nicotinic receptors and cognitive function in early Alzheimer’s disease: A 2-[18F]fluoro-A-85380 PET study
Ellis, J. R., Villemagne, V. L., Nathan, P. J., Mulligan, R. S., Gong, S., Chan, J. G., Sachinidis, J. I., O'Keefe, G., Pathmaraj, K., Wesnes, K. A., et al. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.05.006 · Cited by 57
Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease
Wang, Y., Klunk, W. E., Huang, G.-F., Debnath, M. L., Holt, D. P., & Mathis, C. A. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0004-8 · Cited by 57
Intracellular calcium signalling in Alzheimer’s disease
Hermes, M., Eichhoff, G., & Garaschuk, O. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00976.x · Cited by 57
The Concentration of Soluble Extracellular Amyloid-β Protein in Acute Brain Slices from CRND8 Mice
Waters, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015709 · Cited by 60
Neurodegeneration and Alzheimer’s disease: the lesson from tauopathies
Sorrentino, G., & Bonavita, V. (2007) · Neurological Sciences · doi:10.1007/s10072-007-0789-x · Cited by 56
Stable β-Secretase Activity and Presynaptic Cholinergic Markers During Progressive Central Nervous System Amyloidogenesis in Tg2576 Mice
Gau, J., Steinhilb, M. L., Kao, T.-C., D’Amato, C. J., Gaut, J. R., Frey, K. A., & Turner, R. S. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64893-6 · Cited by 56
Suppressed expression of nicotinic acetylcholine receptors by nanomolar β-amyloid peptides in PC12 cells
Guan, Z. Z., Miao, H., Tian, J., Unger, C., Nordberg, A. K., & Zhang, X. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100017 · Cited by 56
Alzheimer β Amyloid Deposition Enhanced by ApoE ɛ4 Gene precedes Neurofibrillary pathology in the Frontal Association Cortex of Nondemented Senior Subjects
Yamaguchi, H., Sugihara, S., Ogawa, A., Oshima, N., & Ihara, Y. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.7.731 · Cited by 56
Contribution of neural networks to Alzheimer disease's progression
Savioz, A., Leuba, G., Vallet, P. G., & Walzer, C. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.06.006 · Cited by 59
β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis
Murray, P. S., Kirkwood, C. M., Gray, M. C., Ikonomović, M. D., Paljug, W. R., Abrahamson, E. E., Henteleff, R. A., Hamilton, R. L., Kofler, J., Klunk, W. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.015 · Cited by 58
Astrocyte signaling and neurodegeneration
Brambilla, L., Martorana, F., & Rossi, D. (2013) · Prion · doi:10.4161/pri.22512 · Cited by 58
Alzheimer’s disease in people with Down’s syndrome: the prospects for and the challenges of developing preventative treatments
Castro, P., Zaman, S. H., & Holland, A. J. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8308-8 · Cited by 59
Abnormal dendritic calcium activity and synaptic depotentiation occur early in a mouse model of Alzheimer’s disease
Bai, Y., Li, M., Zhou, Y., Ma, L., Qiao, Q., Hu, W., Li, W., Wills, Z. P., & Gan, W. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0228-2 · Cited by 56
Interaction with Amyloid β Peptide Compromises the Lipid Binding Function of Apolipoprotein E
Tamamizu‐Kato, S., Cohen, J. K., Drake, C. B., Kosaraju, M. G., Drury, J., & Narayanaswami, V. (2008) · Biochemistry · doi:10.1021/bi702097s · Cited by 56
Alterations in β-amyloid production and deposition in brain regions of two transgenic models
Lehman, E. J. H., Kulnane, L. S., & Lamb, B. T. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00153-7 · Cited by 55
Phenserine
Klein, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1087 · Cited by 56
Correlation between Cognitive Impairment and CSF Biomarkers in Amnesic MCI, non-Amnesic MCI, and Alzheimer's Disease
Haldenwanger, A., Eling, P., Kastrup, A., & Hildebrandt, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101203 · Cited by 54
Amyloid Beta Inhibits Olfactory Bulb Activity and the Ability to Smell
Alvarado-Martínez, R., Salgado-Puga, K., & Peña‐Ortega, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075745 · Cited by 54
Mutations That Replace Aromatic Side Chains Promote Aggregation of the Alzheimer’s Aβ Peptide
Armstrong, A. H., Chen, J., McKoy, A. F., & Hecht, M. H. (2011) · Biochemistry · doi:10.1021/bi200268w · Cited by 56
Sideritis spp. Extracts Enhance Memory and Learning in Alzheimer’s β-Amyloidosis Mouse Models and Aged C57Bl/6 Mice
Hofrichter, J., Krohn, M., Schumacher, T., Lange, C., Feistel, B., Walbroel, B., & Pahnke, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160301 · Cited by 57
Cortical biochemistry in MCI and Alzheimer disease
Forman, M. S., Mufson, E. J., Leurgans, S. E., Praticò, D., Joyce, S. C., Leight, S., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Neurology · doi:10.1212/01.wnl.0000256373.39415.b1 · Cited by 54
Dibenzothiazoles as novel amyloid-imaging agents
Wu, C., Wei, J., Gao, K., & Wang, Y. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.11.022 · Cited by 54
β‐Amyloid Induces Oxidative DNA Damage and Cell Death through Activation of c‐Jun N Terminal Kinase
Jang, J.-H., & Surh, Y. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04639.x · Cited by 54
Impairment of Hippocampal CA1 Heterosynaptic Transformation and Spatial Memory by β-Amyloid25–35
Sun, M., & Alkon, D. L. (2002) · Journal of Neurophysiology · doi:10.1152/jn.00230.2001 · Cited by 54
Tau acts as a mediator forAlzheimer's disease‐related synaptic deficits
Liao, D., Miller, E. C., & Teravskis, P. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12504 · Cited by 53
Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways
Elbert, D. L., Patterson, B. W., Lucey, B. P., Benzinger, T. L. S., & Bateman, R. J. (2022) · Communications Biology · doi:10.1038/s42003-022-03037-0 · Cited by 53
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?
Mosconi, L., & McHugh, P. F. (2011) · PubMed · Cited by 54
Aβ1–42 reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: A quantitative analysis
Evans, N. A., Facci, L., OWEN, D. E., Soden, P. E., Burbidge, S. A., Prinjha, R. K., Richardson, J. C., & Skaper, S. D. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.08.001 · Cited by 56
Aβ1–42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD
Masliah, E., Alford, M. F., Adame, A., Rockenstein, E. M., Galasko, D., Salmon, D. P., Hansen, L. A., & Thal, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000073987.79060.4b · Cited by 53
Cycle checkpoint abnormalities during dementia: a plausible association with the loss of protection against oxidative stress in Alzheimer’s disease
Katsel, P., Tan, W., Fam, P., Purohit, D. P., & Haroutunian, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068361 · Cited by 52
Cerebral Microvascular Rather than Parenchymal Amyloid-β Protein Pathology Promotes Early Cognitive Impairment in Transgenic Mice
Xu, W., Xu, F., Anderson, M. E., Kotarba, A. E., Davis, J., Robinson, J. K., & Nostrand, W. E. V. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130758 · Cited by 52
Neuropathology of Alzheimer's Disease
Gómez‐Isla, T., Spires‐Jones, T. L., de Calignon, A., & Hyman, B. T. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01222-5 · Cited by 55
Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development
Savonenko, A. V., Melnikova, T., Hiatt, A., Li, T., Worley, P. F., Troncoso, J. C., Wong, P. C., & Price, D. L. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.211 · Cited by 52
Receptor-Mediated Abeta Amyloid Antibody Targeting to Alzheimer’s Disease Mouse Brain
Zhou, Q.-H., Fu, A., Boado, R. J., Hui, E. K., Lu, J. Z., & Pardridge, W. M. (2010) · Molecular Pharmaceutics · doi:10.1021/mp1003515 · Cited by 52
Isolating Pathogenic Mechanisms Embedded within the Hippocampal Circuit through Regional Vulnerability
Small, S. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.030 · Cited by 55
Alzheimer’s disease: relevant molecular and physiopathological events affecting amyloid-β brain balance and the putative role of PPARs
Zolezzi, J. M., Candia, S. B., Santos, M. J., & Inestrosa, N. C. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00176 · Cited by 56
Amyloid β Pathology in Alzheimer’s Disease and Schizophrenia
Religa, D., Laudon, H., Styczyńska, M., Winblad, B. G., Näslund, J., & Haroutunian, V. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.5.867 · Cited by 52
Self-citation
Deficient Wnt Signaling and Synaptic Vulnerability in Alzheimer’s Disease: Emerging Roles for the LRP6 Receptor
Buechler, J., & Salinas, P. C. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00038 · Cited by 53
Contribution of syndecans to cellular internalization and fibrillation of amyloid-β(1–42)
Letoha, T., Hudák, A., Kúsz, E., Pettkó‐Szandtner, A., Domonkos, I., Jósvay, K., Hofmann‐Apitius, M., & Szilák, L. (2019) · Scientific Reports · doi:10.1038/s41598-018-37476-9 · Cited by 52
Neuronal and Nonneuronal Quantitative BACE Immunocytochemical Expression in the Entorhinohippocampal and Frontal Regions in Alzheimer’s Disease
Leuba, G., Wernli, G., Vernay, A., Kraftsik, R., Mohajeri, M. H., & Saini, K. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000083496 · Cited by 52
A Novel Neurotrophic Agent, T-817MA [1-{3-[2-(1-Benzothiophen-5-yl) Ethoxy] Propyl}-3-azetidinol Maleate], Attenuates Amyloid-β-Induced Neurotoxicity and Promotes Neurite Outgrowth in Rat Cultured Central Nervous System Neurons
Hirata, K., Yamaguchi, H., Takamura, Y., Takagi, A., Fukushima, T., Iwakami, N., Saitoh, A., Nakagawa, M., & Yamada, T. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.083543 · Cited by 52
A Vascular Connection to Alzheimer's Disease
Rhodin, J. A. G., & Thomas, T. R. (2001) · Microcirculation · doi:10.1080/713774033 · Cited by 53
Impaired behavior of female tg-ArcSwe APP mice in the IntelliCage: A longitudinal study
Codita, A., Gumucio, A., Lannfelt, L., Gellerfors, P., Winblad, B. G., Mohammed, A. H. S., & Nilsson, L. N. G. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.06.034 · Cited by 52
Label-free electrochemical detection of Amyloid beta aggregation in the presence of iron, copper and zinc
Hung, V. W. S., Masoom, H., & Kerman, K. (2012) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2012.05.023 · Cited by 51
Vaccination as a Therapeutic Approach to Alzheimer's Disease
Wısnıewskı, T., & Boutajangout, A. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20156 · Cited by 53
Individual aggregates of amyloid beta induce temporary calcium influx through the cell membrane of neuronal cells
Drews, A., Flint, J. A., Shivji, N., Jönsson, P., Wirthensohn, D. C., Genst, E. D., Vincke, C., Muyldermans, S., Dobson, C., & Klenerman, D. (2016) · Scientific Reports · doi:10.1038/srep31910 · Cited by 52
Clusterin Is Required for β-Amyloid Toxicity in Human iPSC-Derived Neurons
Robbins, J. P., Perfect, L., Ribé, E. M., Maresca, M., Dangla-Valls, A., Foster, E. M., Killick, R., Nowosiad, P., Reid, M. J., Polit, L. D., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00504 · Cited by 53
Luteinizing Hormone Levels Are Positively Correlated with Plasma Amyloid-β Protein Levels in Elderly Men
Verdile, G., Yeap, B. B., Clarnette, R., Dhaliwal, S. S., Burkhardt, M. S., Chubb, S. A. P., Ruyck, K. D., Rodrigues, M. A., Mehta, P. D., Foster, J. K., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14208 · Cited by 53
Translational Research on the Way to Effective Therapy for Alzheimer Disease
Rosenberg, R. N. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1186 · Cited by 51
Pathophysiology of Parkinson's disease behavior – a view from the network
Caviness, J. N. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70012-9 · Cited by 50
Decreased rabphilin 3A immunoreactivity in Alzheimer’s disease is associated with Aβ burden
Tan, M. G. K., Lee, C., Lee, J. H., Francis, P. T., Williams, R. J., Ramírez, M. J., Chen, C., Wong, P. T. ‐., & Lai, M. K. P. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.10.013 · Cited by 50
The therapeutic potential of the endocannabinoid system for Alzheimer's disease
Karl, T., Cheng, D., Garner, B., & Arnold, J. C. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.671812 · Cited by 51
S 24795 Limits β-Amyloid–α7 Nicotinic Receptor Interaction and Reduces Alzheimer's Disease-Like Pathologies
Wang, H.-Y., Bakshi, K. P., Shen, C., Frankfurt, M., Trocmé, C., & Morain, P. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.031 · Cited by 50
The Ups and Downs of the Posteromedial Cortex: Age- and Amyloid-Related Functional Alterations of the Encoding/Retrieval Flip in Cognitively Normal Older Adults
Vannini, P., Hedden, T., Huijbers, W., Ward, A. M., Johnson, K. A., & Sperling, R. A. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhs108 · Cited by 52
Persistent Infection with Herpes Simplex Virus 1 and Alzheimer’s Disease—A Call to Study How Variability in Both Virus and Host may Impact Disease
Mangold, C. A., & SZPARA, M. L. (2019) · Viruses · doi:10.3390/v11100966 · Cited by 53
Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol
Petanceska, S. S., DeRosa, S., Sharma, A., Diaz, N. S., Duff, K., Tint, S. G., Refolo, L. M., & Pappolla, M. A. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:395 · Cited by 52
Apolipoprotein E co-localizes with newly formed amyloid β-protein (Aβ) deposits lacking immunoreactivity against N-terminal epitopes of Aβ in a genotype-dependent manner
Thal, D. R., Capetillo-Zarate, E., Schultz, C., Rüb, U., Saido, T. C., Yamaguchi, H., Haass, C., Griffin, W. S. T., Del Tredici, K., Braak, H., et al. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1053-1 · Cited by 50
Alzheimer's β-amyloid peptide as a source of neurotoxic free radicals: the role of structural effects
Pogocki, D. (2003) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2003-1463 · Cited by 50
Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-β in vitro
Bergamaschini, L., Donarini, C., Rossi, E., De Luigi, A., Vergani, C., & Grazia De Simoni, M. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00003-9 · Cited by 40
In vivo amyloid imaging in Alzheimer?s disease
Sair, H. I., Doraiswamy, P. M., & Petrella, J. R. (2004) · Neuroradiology · doi:10.1007/s00234-003-1034-9 · Cited by 50
Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets
Pei, J.-J., Sjögren, M., & Winblad, B. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328314b78b · Cited by 49
Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep–Wake Cycle Disorder
Alhusaini, M., Eissa, N., Saad, A. K., Beiram, R., & Sadek, B. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.861094 · Cited by 51
Altered oxidant-mediated intraneuronal zinc mobilization in a triple transgenic mouse model of Alzheimer’s disease
Sensi, S. L., Rapposelli, I. G., Frazzini, V., & Mascetra, N. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.10.018 · Cited by 49
Oligomerization Partially Explains the Lowering of Aβ42 in Alzheimer’s Disease Cerebrospinal Fluid
Englund, H., Gunnarsson, M. D., Brundin, R., Hedlund, M., Kilander, L., Lannfelt, L., & Pettersson, F. E. (2009) · Neurodegenerative Diseases · doi:10.1159/000225376 · Cited by 49
Is there a neuropathology difference between mild cognitive impairment and dementia?
Haroutunian, V. H., Hoffman, L. B., & Been, M. S. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/vharoutunian · Cited by 52
The role of amyloidogenic protein oligomerization in neurodegenerative disease
Lotz, G. P., & Legleiter, J. A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1025-1 · Cited by 49
Amyloid β and neuromelanin—Toxic or protective molecules?The cellular context makes the difference
Rao, K. S. J., Hegde, M. L., Anitha, S., Musicco, M., Zucca, F. A., TURRO, N. J., & Zecca, L. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.03.004 · Cited by 49
Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice
Carty, N., Wilcock, D. M., Rosenthal, A., Grimm, J., Pons, J., Ronan, V., Gottschall, P. E., Gordon, M. N., & Morgan, D. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-11 · Cited by 50
The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-β Levels: Resolubilization of amyloid-β with transition metal ion chelators
Fonte, J., Miklossy, J., Atwood, C., & Martins, R. N. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3206 · Cited by 49
Decreased drebrin mRNA expression in Alzheimer disease: Correlation with tau pathology
Julien, C., Tremblay, C., Bendjelloul, F., Phivilay, A., Coulombe, M., Émond, V., & Calon, F. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21667 · Cited by 51
Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.
Truong, A. P., Tóth, G., Probst, G., Sealy, J., Bowers, S., Wone, D. W. G., Dressen, D., Hom, R. K., Konradi, A., Sham, H., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.102 · Cited by 49
A Foldamer-Dendrimer Conjugate Neutralizes Synaptotoxic β-Amyloid Oligomers
Fülöp, L., Mándity, I. M., Juhász, G., Szegedi, V., Hetényi, A., Wéber, E., Bozsó, Z., Simon, D., Benkő, M., Király, Z., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039485 · Cited by 48
IgG‐single chain Fv fusion protein therapeutic for alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey
Boado, R. J., Lu, J. Z., Hui, E. K., & Pardridge, W. M. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22576 · Cited by 48
BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics
Seabrook, G. R., Ray, W. J., Shearman, M. S., & Hutton, M. L. (2007) · Molecular Interventions · doi:10.1124/mi.7.5.8 · Cited by 48
Assembly of Peptides Derived from β-Sheet Regions of β-Amyloid
Truex, N. L., Wang, Y., & Nowick, J. S. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b06000 · Cited by 50
PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis
Wang, H.-Y., Lee, K.-C., Pei, Z., Khan, A., Bakshi, K. P., & Burns, L. H. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.016 · Cited by 48
Retracted
The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease
Pawlik, P., & Błochowiak, K. J. (2021) · Diagnostics · doi:10.3390/diagnostics11020371 · Cited by 48
The palmitoyl groups of lung surfactant protein C reduce unfolding into a fibrillogenic intermediate
Gustafsson, M., Griffiths, W. J., Furusjö, E., & Johansson, J. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4810 · Cited by 48
Isomerization of (Z,Z) to (E,E)1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in Strong Base: Probes for Amyloid Plaques in the Brain
Lee, C., Zhuang, Z., Kung, M., Plöessl, K., Skovronsky, D., Gur, T., Hou, C., Trojanowski, J. Q., Lee, V. M. ‐., & Kung, H. F. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010161t · Cited by 48
ATG5 (autophagy related 5) in microglia controls hippocampal neurogenesis in Alzheimer disease
Tang, X., Walter, E., Wohleb, E., Fan, Y., & Wang, C. (2024) · Autophagy · doi:10.1080/15548627.2023.2277634 · Cited by 43
Neuroimaging Results Impose New Views on Alzheimer’s Disease—the Role of Amyloid Revised
Fjell, A. M., & Walhovd, K. B. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8228-7 · Cited by 48

Authors: Näslund, J.
Affiliations: Rockefeller University (US)
Corresponding author: Näslund, Jan
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2000-03-22
Volume: 283
Issue: 12
Pages: 1571
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.283.12.1571
OpenAlex: W2000706612
Cited by: 1,268
References: 28
Citations by year: 2026: 9 · 2025: 14 · 2024: 32 · 2023: 23 · 2022: 28 · 2021: 32 · 2020: 31 · 2019: 29 · 2018: 34 · 2017: 29 · 2016: 57 · 2015: 56 · 2014: 60 · 2013: 59 · 2012: 65
FWCI: 40.95
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Aging (AG-02219, AG 05138, P50AG005138, AG 14996, P01AG002219)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: amyloid-beta, Alzheimer's disease, cognitive decline, dementia progression, tau protein, amyloid-beta 42, Aβ40, frontal cortex, Clinical Dementia Rating, postmortem brain, neocortex, nursing home residents, amyloid plaques, neurofibrillary tangles
MeSH terms: Aged, Aged, 80 and over, Brain, Cognition Disorders, Cross-Sectional Studies, Dementia, Enzyme-Linked Immunosorbent Assay, Female, Frontal Lobe, Humans, Immunoenzyme Techniques, Male, Immunoblotting, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks